{"title": "PDF", "author": "PDF", "url": "https://eprints.nottingham.ac.uk/14013/1/334866.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "IMPLEMENTATION OFBAYESIAN METHODS INTHEPHARMACEUTICAL INDUSTRY Patient 1 2 PL~TN 19 3 10 TN-+PL 20 12 16 22 8 6 21 4 11 24 6 4 23 6 5 35 1 0 36 7 14 38 12 6 37 13 25 39 4 2 40 9 11 42 6 3 41 1 1 59 11 3 43 4 0 64 3 4 56 4 10 73 11 3 57 2 5 76 8 8 60 0 8 78 8 9 61 17 13 80 18 4 65 1 1 81 12 5 67 6 8 84 12 2 75 8 8 85 3 1 77 7 4 115 1 3 79 3 19 122 12 4 82 4 19 124 8 6 83 3 12 126 7 12 86 2 4 128 1 1 87 2 1 140 2 0 121 4 7 142 3 0 123 3 1 146 21 10 125 3 3 147 17 7 127 1 0 150 12 5 130 41 36 201 4 5 145 10 24 209 0 1 148 9 18 211 7 0 149 4 13 233 11 0 210 8 1 236 18 7 234 5 7 235 0 9 0.00 14 14.50 19.75 13.00 9.25 4.25 6.00 2.75 17 10.00 10.75 14.50 10.75 20 10.50 8.50 6.00 4.25 22 19.50 15.00 14.50 8.00 24 7.50 4.25 0.00 3.50 ISDN....TN 3 21.00 21.50 22.00 38.00 5 10.50 5.25 3.50 2.50 7 3.50 2.00 1.50 4.50 9 10.00 16.75 9.50 18.25 13 1.50 1.50 0.50 0.75 16 6.00 3.25 2.00 2.50 18 1.50 0.00 0.00 0.00 21 3.50 1.00 3.50 8.00 23 9.50 0.50 1.50 25 Periods Group 1 L-LC-LC 2 103 96 84LC-L-L 3 9590 30 54 119 90 8090182 9895 128 94102 96204 100 90 82 136 100105110205 90 98 149 808580210 90 90100 183 9580105L-LC-L 1 100 96 96 189 80 888019 100 90 84 197 90 9890LC-L-LC 99 92 8170 90 80 95 7 118 899282 100 94 102 13 90909095 100 84 118 55 9080 84100 100 178 90 90 85190 9484 92 203 909080201 92 7580 207 92 100 96214 80 80 85 211 80 80 80219 106112 80 60 40 20 20 60 80 100 40 ~ FIGURE 4.1Posterior Dl.tributlon ofVariance Camonent. 0.0 0.2 0.4 FIGURE 4.3Influence ofVariance o -1+-----.---------.------,------.--------+ 0.0 0.0 0.2 0.4 0.6 0.8 1.0 Prior Belief in0Carryover Effect 0.4 0.2 o 2 3 -2 -1 4 5 Treatment Effect FIGURE 4.6Dependence 116 1/6 1/6 1/6 1111 Y 1/2 0 Period PeriodII Sequence Patient Baseline 12Sequence Patient Baseline 1 2 V~ 106 1425 25 I-N 102 12 910 111 9 9 4 104 12 810 206 8 4 8 105 1921 16 207 9 8 7 107 1011 12 210 1 17 112 3334 36 211 2025 16 202 2 3 0 301 3 7 8 203 19 8 11 304 3 4 5 205 4039 39 306 2 1 2 208 1 0 0 308 4 4 2 209 2021 35 309 2 0 4 212 1 0 1 311 3 0 0 302 2 6 6 331 6 66 307 4 2 3 334 1 11 312 7 4 1 335 2 0 0 315 9 0 0 401 11 53 332 4 2 4 408 16 0 0 333 9 6 6 410 24 16 10 402 65 5 411 16 312 406 1417 16 414 21 18 18 407 8 3 0 415 19 611 409 2723 25 432 22 10 7 412 10 6 7 434 3322 19 413 27 8 8 501 1215 11 433 7 2 0 435 24 827 502 21 18 0.5 1 0.201 1/4 0.502 0.9 119 0.694 -------------_---......._--...~~--~ -2+------.-----.------~-----.------+ 0.0 0.0 0.2 0.4 0.6 0.8 1.0 Prior Belief in0Corryover Effect FIGURE 5.2Posterior 9.00 15 2.00 9.00 7.50 5.50 20 10.00 8.50 6.00 4.25 22 14.00 2.00 2.00 1.25 24 5.50 2.50 1.50 2.50 ISDN~TN 3 17.50 19.25 19.00 21.25 5 11.00 6.50 3.00 9 11.00 16.50 10.00 18.25 13 6.50 4.25 0.50 2.00 4.00 18 1.00 0.00 0.00 0.00 21 3.00 0.75 3.00 5.25 23 9.50 1.00 0.50 8.50 25 10.50 13 Ma \"C 3/8 A- A. 2 o a 39/8 (1:A-) (\"CA.) 3/8 M2 - 3/8 1: 1: A- A. 2 e a 39/8 Mil \"C ;;-3(J/13 2 FIGURE 7.2Treatment Posterior Tablet). Period Period Sequence Subject 1 2 Sequence Subject 1 2 C~ 1 5.19 4.07 S-IC 3 4.21 AnimalsExposed Animals Dying 500 5 1 1000 5 2 2500 5 3 5000 5 2 ToxicityClasses 4 5 mglkg Probabilities 0.01 0.04 0.10 0.35 0.40 0.10 13 6 -17 -18~----~----~----~~~~~--~----~----~----~-20 -15 -10 -5 0 5 10 15 20 Log(L050) FIGURE 11.6 Profile Number of (mg'/kg.) Animals Exposed Animals Dying 600 10 0 1 1()()() 10 6 1470 10 8 1670 10 10 600 10 0 2 775 10 5 850 10 6 1()()() 10 10 359 10 1 600 10 2 3 1000 10 7 2150 10 10 3590 Number of (mg'/kg.) Animals Exposed Animals Dying 35.9 5 0 60 5 0 Males 129 5 2 147 5 4 215 5 5 35.9 10 0 60 10 5 Males 129 10 7 andFemales 147 10 9 215 10 10 Theseresultsgaverisetothetraditional maximum likelihood resultsdisplayed inTable12.4 Limit 1 0.000 TABLE 12.7Predictive Distributions ofrDeathsfrom10Animals Receiving 35mglkg.ofMiral.3 Males&Females Batch n r n r 1 5 0 10 0 2 5 0 10 0 3 5 1 10 3 4 5 0 10 0 5 5 0 10 0 6 5 0 10 2 Thisassumption isparticularly important since,aswehaveseen,theLDSOisnotabiological 1.5 1 ~ 7 .u;cCl> 0 ....1.00 \u00b7cCl> ......en 0 0.... 0.5 13-3 DISCUSSION.1.4~-------------------------------------------------------, 1.2 1.0 0.8 Q) Cl.. 0 (/) ) 0.4 0.2 00\\ ONOM ON ON ON 00gg0000 00 ....,000 MOOO ..,0 deioo 0000 0000 0000 0000 0000 0000 0000 -.2 1 .004 .062 .002 .101 2 .007 .080 .006 .126 0 1 .032 .134 .037 .196 2 .032 .134 .037 .196 .2 1 .146 .229 .225 .310 2 .099 .200 .146 .276 .5 1 .536 .373 .771 .465 2 .323 .306 .507 .394 10 0 1 .040 .233 .042 .278 2 .040 .233 .042 .278 .5 1 2 ILOOP CARD PRIOR CARD 4 4 43 ;44; 3 C3 effect T-Treatment effect P_CON-Constrained Conditional Density DATASET D T-Treatment effect PUNC-Unconstrained Conditional Density P=CON-Constrained Conditional Density DATASET E T-Treatment effect PUNC-Unconstrained Density P=CON-Constrained Density DATASET F R-Carryover effect Density Density G "}